Tags

Type your tag names separated by a space and hit enter

Postmarketing surveillance for "modified-risk" tobacco products.
Nicotine Tob Res. 2012 Jan; 14(1):29-42.NT

Abstract

INTRODUCTION

The U.S. Food and Drug Administration (FDA) acquired authority to regulate tobacco products in 2009. This authority will provide a structured process for manufacturers to introduce products that may have "modified-risk" for morbidity or mortality relative to traditional tobacco products, with postmarketing surveillance and studies a condition of marketing.

METHOD

A narrative review approach was taken. The author searched and integrated publicly accessible literature on tobacco product surveillance as well as drug and medical device postmarket activities currently performed by FDA.

RESULTS

FDA relies on active and passive methods for postmarket surveillance and can require specific studies and risk evaluation and mitigation strategies for certain products, including those with abuse liability. Past efforts at examining the individual and population effects of reduced harm tobacco products provide an example of integrating different data streams.

DISCUSSION

Postmarket surveillance can be viewed in terms of the Agent-Host-Vector-Environment model, and concepts from diffusion of innovations are relevant to understanding factors associated with the adoption of new products by the population. Given that active and passive surveillance approaches have different strengths and weaknesses, multiple approaches may be necessary to evaluate population-level effects. Assuring that required studies are properly conducted and reported and that data indicating significant public health harms are quickly recognized will be important going forward.

CONCLUSIONS

The advent of broad regulatory authority over tobacco provides opportunities for policy evaluation research. The research community can provide FDA with the independent science it needs to evaluate the public health impact of novel tobacco products.

Authors+Show Affiliations

Department of Health Behavior, Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. richard.oconnor@roswellpark.org

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

21330282

Citation

O'Connor, Richard J.. "Postmarketing Surveillance for "modified-risk" Tobacco Products." Nicotine & Tobacco Research : Official Journal of the Society for Research On Nicotine and Tobacco, vol. 14, no. 1, 2012, pp. 29-42.
O'Connor RJ. Postmarketing surveillance for "modified-risk" tobacco products. Nicotine Tob Res. 2012;14(1):29-42.
O'Connor, R. J. (2012). Postmarketing surveillance for "modified-risk" tobacco products. Nicotine & Tobacco Research : Official Journal of the Society for Research On Nicotine and Tobacco, 14(1), 29-42. https://doi.org/10.1093/ntr/ntq243
O'Connor RJ. Postmarketing Surveillance for "modified-risk" Tobacco Products. Nicotine Tob Res. 2012;14(1):29-42. PubMed PMID: 21330282.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Postmarketing surveillance for "modified-risk" tobacco products. A1 - O'Connor,Richard J, Y1 - 2011/01/20/ PY - 2011/2/19/entrez PY - 2011/2/19/pubmed PY - 2012/9/6/medline SP - 29 EP - 42 JF - Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco JO - Nicotine Tob. Res. VL - 14 IS - 1 N2 - INTRODUCTION: The U.S. Food and Drug Administration (FDA) acquired authority to regulate tobacco products in 2009. This authority will provide a structured process for manufacturers to introduce products that may have "modified-risk" for morbidity or mortality relative to traditional tobacco products, with postmarketing surveillance and studies a condition of marketing. METHOD: A narrative review approach was taken. The author searched and integrated publicly accessible literature on tobacco product surveillance as well as drug and medical device postmarket activities currently performed by FDA. RESULTS: FDA relies on active and passive methods for postmarket surveillance and can require specific studies and risk evaluation and mitigation strategies for certain products, including those with abuse liability. Past efforts at examining the individual and population effects of reduced harm tobacco products provide an example of integrating different data streams. DISCUSSION: Postmarket surveillance can be viewed in terms of the Agent-Host-Vector-Environment model, and concepts from diffusion of innovations are relevant to understanding factors associated with the adoption of new products by the population. Given that active and passive surveillance approaches have different strengths and weaknesses, multiple approaches may be necessary to evaluate population-level effects. Assuring that required studies are properly conducted and reported and that data indicating significant public health harms are quickly recognized will be important going forward. CONCLUSIONS: The advent of broad regulatory authority over tobacco provides opportunities for policy evaluation research. The research community can provide FDA with the independent science it needs to evaluate the public health impact of novel tobacco products. SN - 1469-994X UR - https://www.unboundmedicine.com/medline/citation/21330282/Postmarketing_surveillance_for_"modified_risk"_tobacco_products_ L2 - https://academic.oup.com/ntr/article-lookup/doi/10.1093/ntr/ntq243 DB - PRIME DP - Unbound Medicine ER -